Eric Poeschla
Concepts (525)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunodeficiency Virus, Feline | 30 | 2023 | 34 | 7.180 |
Why?
| | HIV-1 | 39 | 2022 | 887 | 4.570 |
Why?
| | Genetic Vectors | 28 | 2013 | 335 | 4.150 |
Why?
| | Virus Integration | 20 | 2022 | 69 | 2.860 |
Why?
| | RNA, Viral | 14 | 2025 | 688 | 2.670 |
Why?
| | HIV Integrase | 14 | 2022 | 70 | 2.550 |
Why?
| | Virus Replication | 28 | 2022 | 528 | 2.430 |
Why?
| | Cats | 26 | 2023 | 223 | 2.090 |
Why?
| | Intercellular Signaling Peptides and Proteins | 14 | 2022 | 384 | 2.050 |
Why?
| | Lentiviruses, Primate | 4 | 2023 | 12 | 1.870 |
Why?
| | Lentivirus | 12 | 2022 | 59 | 1.840 |
Why?
| | Interferons | 3 | 2025 | 203 | 1.590 |
Why?
| | DNA, Viral | 8 | 2022 | 369 | 1.590 |
Why?
| | Interferon-Induced Helicase, IFIH1 | 3 | 2025 | 18 | 1.550 |
Why?
| | Genetic Therapy | 13 | 2013 | 310 | 1.420 |
Why?
| | Immunity, Innate | 7 | 2020 | 826 | 1.380 |
Why?
| | Cell Line | 36 | 2020 | 2865 | 1.380 |
Why?
| | Picornaviridae | 3 | 2020 | 20 | 1.330 |
Why?
| | Chromatin | 9 | 2016 | 517 | 1.250 |
Why?
| | Reverse Transcription | 4 | 2021 | 20 | 1.120 |
Why?
| | RNA, Double-Stranded | 2 | 2025 | 55 | 1.070 |
Why?
| | RNA-Binding Proteins | 3 | 2025 | 427 | 1.060 |
Why?
| | Trabecular Meshwork | 9 | 2014 | 79 | 1.000 |
Why?
| | Antibodies, Viral | 2 | 2020 | 648 | 0.990 |
Why?
| | RNA Interference | 8 | 2020 | 468 | 0.980 |
Why?
| | Lentivirus Infections | 4 | 2014 | 9 | 0.970 |
Why?
| | Retroviridae | 5 | 2022 | 102 | 0.950 |
Why?
| | RNA Editing | 1 | 2025 | 24 | 0.940 |
Why?
| | Aqueous Humor | 7 | 2009 | 36 | 0.930 |
Why?
| | Adenosine Deaminase | 1 | 2025 | 35 | 0.930 |
Why?
| | Haploinsufficiency | 1 | 2025 | 56 | 0.930 |
Why?
| | Gene Products, gag | 3 | 2012 | 38 | 0.920 |
Why?
| | Gene Transfer Techniques | 10 | 2011 | 175 | 0.920 |
Why?
| | Adaptor Proteins, Signal Transducing | 7 | 2020 | 430 | 0.890 |
Why?
| | HIV Infections | 15 | 2022 | 2945 | 0.860 |
Why?
| | Virus Assembly | 6 | 2014 | 79 | 0.860 |
Why?
| | Virion | 7 | 2022 | 113 | 0.850 |
Why?
| | Integrases | 5 | 2022 | 120 | 0.840 |
Why?
| | Animals | 60 | 2025 | 37151 | 0.780 |
Why?
| | Transgenes | 8 | 2009 | 185 | 0.740 |
Why?
| | Capsid | 7 | 2022 | 90 | 0.740 |
Why?
| | Host-Pathogen Interactions | 6 | 2021 | 376 | 0.710 |
Why?
| | Molecular Sequence Data | 19 | 2014 | 2925 | 0.680 |
Why?
| | Gammaretrovirus | 1 | 2020 | 2 | 0.680 |
Why?
| | Spumavirus | 1 | 2020 | 3 | 0.680 |
Why?
| | Recombinant Fusion Proteins | 6 | 2011 | 662 | 0.660 |
Why?
| | Teicoplanin | 1 | 2020 | 15 | 0.650 |
Why?
| | HIV | 6 | 2012 | 246 | 0.640 |
Why?
| | Chiroptera | 1 | 2020 | 63 | 0.630 |
Why?
| | Transcription Factors | 7 | 2020 | 1709 | 0.620 |
Why?
| | Prisons | 1 | 2020 | 86 | 0.620 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2020 | 69 | 0.620 |
Why?
| | Liver Diseases, Parasitic | 1 | 2019 | 2 | 0.610 |
Why?
| | Fascioliasis | 1 | 2019 | 4 | 0.610 |
Why?
| | Humans | 99 | 2025 | 138102 | 0.610 |
Why?
| | Antibodies, Neutralizing | 2 | 2022 | 302 | 0.600 |
Why?
| | Exodeoxyribonucleases | 1 | 2018 | 22 | 0.580 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 370 | 0.580 |
Why?
| | Nucleotidyltransferases | 1 | 2018 | 27 | 0.580 |
Why?
| | Retroviridae Infections | 3 | 2020 | 48 | 0.570 |
Why?
| | Coronavirus Infections | 2 | 2020 | 368 | 0.570 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2014 | 1101 | 0.560 |
Why?
| | Amino Acid Sequence | 10 | 2023 | 2159 | 0.550 |
Why?
| | Betacoronavirus | 1 | 2020 | 270 | 0.530 |
Why?
| | Ferrets | 2 | 2020 | 30 | 0.530 |
Why?
| | Dyspnea | 1 | 2019 | 251 | 0.520 |
Why?
| | Transformation, Genetic | 2 | 2012 | 16 | 0.520 |
Why?
| | Eosinophilia | 1 | 2019 | 217 | 0.510 |
Why?
| | Outpatients | 1 | 2020 | 407 | 0.510 |
Why?
| | Phosphoproteins | 1 | 2018 | 340 | 0.490 |
Why?
| | mRNA Cleavage and Polyadenylation Factors | 4 | 2020 | 27 | 0.480 |
Why?
| | Nuclear Pore Complex Proteins | 2 | 2020 | 36 | 0.470 |
Why?
| | Viral Load | 3 | 2020 | 499 | 0.460 |
Why?
| | Antibodies, Monoclonal | 2 | 2020 | 1419 | 0.460 |
Why?
| | Pandemics | 2 | 2020 | 1639 | 0.450 |
Why?
| | Gene Knockout Techniques | 2 | 2014 | 118 | 0.440 |
Why?
| | DNA, Complementary | 2 | 2013 | 275 | 0.440 |
Why?
| | Cat Diseases | 1 | 2014 | 22 | 0.420 |
Why?
| | Cytosine Deaminase | 2 | 2010 | 16 | 0.420 |
Why?
| | Mice | 20 | 2025 | 17769 | 0.410 |
Why?
| | HIV Integrase Inhibitors | 4 | 2022 | 70 | 0.410 |
Why?
| | Transduction, Genetic | 5 | 2008 | 136 | 0.400 |
Why?
| | Viral Envelope Proteins | 1 | 2014 | 97 | 0.400 |
Why?
| | Glaucoma | 2 | 2009 | 233 | 0.390 |
Why?
| | Animals, Genetically Modified | 2 | 2011 | 244 | 0.390 |
Why?
| | Molecular Chaperones | 1 | 2014 | 193 | 0.370 |
Why?
| | Lentiviruses, Feline | 1 | 2011 | 1 | 0.360 |
Why?
| | Carnivora | 1 | 2011 | 6 | 0.360 |
Why?
| | Primate Diseases | 1 | 2011 | 8 | 0.360 |
Why?
| | Intraocular Pressure | 3 | 2009 | 306 | 0.360 |
Why?
| | Transfection | 7 | 2012 | 938 | 0.360 |
Why?
| | Base Sequence | 11 | 2012 | 2180 | 0.350 |
Why?
| | Monkey Diseases | 1 | 2011 | 25 | 0.350 |
Why?
| | Nuclear Localization Signals | 3 | 2006 | 18 | 0.350 |
Why?
| | Cells, Cultured | 10 | 2012 | 4160 | 0.350 |
Why?
| | Open Reading Frames | 1 | 2012 | 132 | 0.350 |
Why?
| | Mutation | 9 | 2020 | 3994 | 0.340 |
Why?
| | Antigens, CD | 1 | 2014 | 530 | 0.340 |
Why?
| | Gene Expression | 9 | 2013 | 1487 | 0.340 |
Why?
| | Gene Products, vif | 1 | 2010 | 2 | 0.330 |
Why?
| | Green Fluorescent Proteins | 7 | 2011 | 396 | 0.330 |
Why?
| | Cell Nucleus | 5 | 2021 | 612 | 0.330 |
Why?
| | Luminescent Proteins | 4 | 2012 | 181 | 0.330 |
Why?
| | Nerve Tissue Proteins | 1 | 2014 | 596 | 0.330 |
Why?
| | Cytidine Deaminase | 1 | 2010 | 61 | 0.330 |
Why?
| | Active Transport, Cell Nucleus | 6 | 2022 | 122 | 0.330 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1804 | 0.320 |
Why?
| | DNA Viruses | 1 | 2009 | 23 | 0.320 |
Why?
| | Prostaglandins | 1 | 2009 | 101 | 0.310 |
Why?
| | Disease Models, Animal | 5 | 2013 | 4309 | 0.310 |
Why?
| | Purines | 1 | 2010 | 177 | 0.310 |
Why?
| | Gene Knockdown Techniques | 2 | 2016 | 329 | 0.300 |
Why?
| | beta-Galactosidase | 3 | 2004 | 79 | 0.300 |
Why?
| | Eye Proteins | 4 | 2014 | 92 | 0.300 |
Why?
| | RNA, Messenger | 5 | 2023 | 2799 | 0.280 |
Why?
| | HIV-2 | 5 | 2002 | 18 | 0.280 |
Why?
| | Cytoplasm | 5 | 2021 | 267 | 0.280 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2009 | 157 | 0.280 |
Why?
| | Primates | 3 | 2020 | 139 | 0.270 |
Why?
| | Biological Evolution | 1 | 2011 | 491 | 0.270 |
Why?
| | Retina | 3 | 2004 | 302 | 0.260 |
Why?
| | HEK293 Cells | 5 | 2020 | 730 | 0.260 |
Why?
| | Gene Targeting | 2 | 2004 | 82 | 0.250 |
Why?
| | Antiviral Agents | 3 | 2022 | 759 | 0.250 |
Why?
| | Mice, Transgenic | 3 | 2020 | 2166 | 0.240 |
Why?
| | DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2005 | 6 | 0.240 |
Why?
| | Mice, Knockout | 4 | 2025 | 3014 | 0.240 |
Why?
| | Protein Binding | 8 | 2021 | 2232 | 0.230 |
Why?
| | Proteins | 3 | 2007 | 1011 | 0.230 |
Why?
| | Oncogenic Viruses | 1 | 2004 | 3 | 0.230 |
Why?
| | Genes, Reporter | 4 | 2012 | 272 | 0.220 |
Why?
| | HeLa Cells | 7 | 2020 | 635 | 0.220 |
Why?
| | Anti-HIV Agents | 2 | 2022 | 836 | 0.220 |
Why?
| | Cell Culture Techniques | 3 | 2012 | 363 | 0.220 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2020 | 979 | 0.210 |
Why?
| | Terminal Repeat Sequences | 2 | 2020 | 18 | 0.210 |
Why?
| | Pigment Epithelium of Eye | 1 | 2003 | 33 | 0.210 |
Why?
| | Emigration and Immigration | 2 | 2020 | 50 | 0.210 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 1996 | 233 | 0.210 |
Why?
| | Lymphocytes | 4 | 2012 | 392 | 0.210 |
Why?
| | Anti-Retroviral Agents | 1 | 2005 | 245 | 0.210 |
Why?
| | Protein Structure, Tertiary | 5 | 2015 | 864 | 0.200 |
Why?
| | Bone Marrow Stromal Antigen 2 | 1 | 2023 | 2 | 0.200 |
Why?
| | Genome, Viral | 5 | 2019 | 222 | 0.200 |
Why?
| | Human Immunodeficiency Virus Proteins | 1 | 2023 | 6 | 0.200 |
Why?
| | Protein Sorting Signals | 1 | 2023 | 20 | 0.200 |
Why?
| | Viral Regulatory and Accessory Proteins | 1 | 2023 | 28 | 0.200 |
Why?
| | Spike Glycoprotein, Coronavirus | 2 | 2022 | 118 | 0.200 |
Why?
| | Amino Acids | 2 | 2023 | 499 | 0.200 |
Why?
| | Evolution, Molecular | 3 | 2020 | 518 | 0.200 |
Why?
| | RNA, Catalytic | 5 | 1998 | 188 | 0.200 |
Why?
| | GPI-Linked Proteins | 1 | 2023 | 76 | 0.200 |
Why?
| | Caveolins | 1 | 2002 | 6 | 0.200 |
Why?
| | Mutation, Missense | 2 | 2014 | 340 | 0.190 |
Why?
| | Paragonimiasis | 1 | 2002 | 2 | 0.190 |
Why?
| | Paragonimus | 1 | 2002 | 2 | 0.190 |
Why?
| | Cytoskeletal Proteins | 3 | 2008 | 156 | 0.190 |
Why?
| | RNA, Small Interfering | 2 | 2020 | 621 | 0.190 |
Why?
| | Karyopherins | 2 | 2012 | 19 | 0.190 |
Why?
| | Gene Products, env | 3 | 2012 | 6 | 0.190 |
Why?
| | Endemic Diseases | 1 | 2002 | 34 | 0.190 |
Why?
| | Aotidae | 2 | 2020 | 7 | 0.190 |
Why?
| | Genetic Engineering | 1 | 2003 | 93 | 0.190 |
Why?
| | Virus Cultivation | 2 | 2012 | 31 | 0.190 |
Why?
| | Tripartite Motif Proteins | 2 | 2020 | 41 | 0.180 |
Why?
| | Saliva | 1 | 2023 | 239 | 0.180 |
Why?
| | Cytomegalovirus | 3 | 2012 | 159 | 0.180 |
Why?
| | Promoter Regions, Genetic | 4 | 2012 | 1237 | 0.180 |
Why?
| | Dogs | 2 | 2014 | 405 | 0.180 |
Why?
| | Glycoproteins | 3 | 2008 | 357 | 0.170 |
Why?
| | Genes, Viral | 2 | 2015 | 92 | 0.170 |
Why?
| | Cyclophilin A | 1 | 2020 | 26 | 0.170 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2012 | 206 | 0.170 |
Why?
| | Viral Proteins | 3 | 2015 | 361 | 0.170 |
Why?
| | 3T3 Cells | 1 | 2020 | 164 | 0.170 |
Why?
| | Pathogen-Associated Molecular Pattern Molecules | 1 | 2020 | 7 | 0.170 |
Why?
| | Plasmids | 5 | 2012 | 359 | 0.170 |
Why?
| | Immunologic Surveillance | 1 | 2020 | 26 | 0.160 |
Why?
| | Vesicular Transport Proteins | 1 | 2021 | 85 | 0.160 |
Why?
| | Drug Resistance, Viral | 2 | 2014 | 118 | 0.160 |
Why?
| | Hantavirus Pulmonary Syndrome | 1 | 2020 | 5 | 0.160 |
Why?
| | Disease Resistance | 1 | 2020 | 34 | 0.160 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2020 | 35 | 0.160 |
Why?
| | Quarantine | 1 | 2020 | 31 | 0.160 |
Why?
| | Growth Inhibitors | 2 | 2013 | 44 | 0.160 |
Why?
| | Immune Evasion | 1 | 2020 | 58 | 0.160 |
Why?
| | Interferon-beta | 1 | 2020 | 92 | 0.160 |
Why?
| | Immunoassay | 1 | 2020 | 113 | 0.160 |
Why?
| | RNA Virus Infections | 1 | 2019 | 20 | 0.160 |
Why?
| | Immunoblotting | 2 | 2014 | 306 | 0.160 |
Why?
| | Immunity, Humoral | 1 | 2020 | 117 | 0.150 |
Why?
| | Endogenous Retroviruses | 1 | 2020 | 38 | 0.150 |
Why?
| | Ciliary Body | 2 | 2009 | 39 | 0.150 |
Why?
| | Delayed-Action Preparations | 1 | 2020 | 173 | 0.150 |
Why?
| | Embryonic Development | 1 | 2020 | 118 | 0.150 |
Why?
| | Interferon Type I | 1 | 2020 | 141 | 0.150 |
Why?
| | Viremia | 1 | 2020 | 152 | 0.150 |
Why?
| | Sequence Alignment | 2 | 2014 | 360 | 0.150 |
Why?
| | Afghanistan | 1 | 2019 | 71 | 0.150 |
Why?
| | Cell Transformation, Viral | 1 | 1998 | 25 | 0.150 |
Why?
| | THP-1 Cells | 1 | 2018 | 19 | 0.150 |
Why?
| | Monocytes | 2 | 2018 | 563 | 0.150 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2020 | 873 | 0.150 |
Why?
| | RNA Viruses | 1 | 2019 | 76 | 0.140 |
Why?
| | Receptors, CXCR4 | 1 | 1998 | 87 | 0.140 |
Why?
| | Emigrants and Immigrants | 1 | 2020 | 142 | 0.140 |
Why?
| | Transcription, Genetic | 4 | 2016 | 1455 | 0.140 |
Why?
| | Genes, vif | 2 | 2010 | 3 | 0.140 |
Why?
| | Renal Insufficiency | 1 | 2020 | 161 | 0.140 |
Why?
| | Protein Transport | 2 | 2012 | 441 | 0.130 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2020 | 239 | 0.130 |
Why?
| | Residence Characteristics | 1 | 2020 | 366 | 0.130 |
Why?
| | T-Lymphocytes | 5 | 2020 | 1983 | 0.130 |
Why?
| | Rats | 7 | 2014 | 5564 | 0.130 |
Why?
| | Genes, Immediate-Early | 2 | 2012 | 22 | 0.130 |
Why?
| | Quinolines | 2 | 2014 | 154 | 0.130 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2020 | 414 | 0.130 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 541 | 0.120 |
Why?
| | Kinetics | 6 | 2013 | 1640 | 0.120 |
Why?
| | Public Health | 1 | 2020 | 589 | 0.120 |
Why?
| | Blotting, Western | 5 | 2015 | 1223 | 0.120 |
Why?
| | Species Specificity | 2 | 2012 | 584 | 0.120 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 648 | 0.110 |
Why?
| | Echinocandins | 1 | 2014 | 7 | 0.110 |
Why?
| | Gene Products, rev | 2 | 2004 | 6 | 0.110 |
Why?
| | Mucormycosis | 1 | 2014 | 22 | 0.110 |
Why?
| | Amphotericin B | 1 | 2014 | 32 | 0.110 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2014 | 87 | 0.110 |
Why?
| | Voriconazole | 1 | 2014 | 18 | 0.110 |
Why?
| | Acetates | 1 | 2014 | 80 | 0.110 |
Why?
| | Gene Expression Regulation | 1 | 2003 | 2586 | 0.110 |
Why?
| | Organ Culture Techniques | 3 | 2006 | 156 | 0.110 |
Why?
| | Sequence Deletion | 2 | 2006 | 182 | 0.110 |
Why?
| | Female | 15 | 2020 | 73648 | 0.110 |
Why?
| | Genes, gag | 2 | 2004 | 4 | 0.110 |
Why?
| | Healthcare Disparities | 1 | 2020 | 662 | 0.110 |
Why?
| | Ocular Hypertension | 1 | 2014 | 67 | 0.110 |
Why?
| | Cyclophilins | 1 | 2014 | 39 | 0.100 |
Why?
| | Polymerase Chain Reaction | 2 | 2014 | 1049 | 0.100 |
Why?
| | Antifungal Agents | 1 | 2014 | 136 | 0.100 |
Why?
| | Retroviridae Proteins | 2 | 2012 | 10 | 0.100 |
Why?
| | Introns | 3 | 2015 | 256 | 0.100 |
Why?
| | Protein Multimerization | 1 | 2014 | 195 | 0.100 |
Why?
| | Rats, Sprague-Dawley | 4 | 2014 | 2472 | 0.100 |
Why?
| | F-Box Proteins | 1 | 2012 | 22 | 0.100 |
Why?
| | Vero Cells | 2 | 2019 | 85 | 0.100 |
Why?
| | Microscopy, Confocal | 2 | 2004 | 322 | 0.100 |
Why?
| | gag Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 11 | 0.100 |
Why?
| | DNA-Binding Proteins | 3 | 2013 | 1477 | 0.090 |
Why?
| | Genes, env | 1 | 2012 | 5 | 0.090 |
Why?
| | Genes, Synthetic | 1 | 2012 | 14 | 0.090 |
Why?
| | Collagen | 1 | 2014 | 454 | 0.090 |
Why?
| | Mink | 1 | 2011 | 12 | 0.090 |
Why?
| | Male | 13 | 2020 | 67984 | 0.090 |
Why?
| | Rabbits | 2 | 2011 | 765 | 0.090 |
Why?
| | Mice, Inbred C57BL | 2 | 2020 | 5769 | 0.090 |
Why?
| | Feline Acquired Immunodeficiency Syndrome | 1 | 2011 | 2 | 0.090 |
Why?
| | bcl-2 Homologous Antagonist-Killer Protein | 1 | 2011 | 15 | 0.090 |
Why?
| | Caspase 8 | 1 | 2011 | 47 | 0.090 |
Why?
| | DNA | 3 | 2005 | 1448 | 0.090 |
Why?
| | bcl-2-Associated X Protein | 1 | 2011 | 56 | 0.090 |
Why?
| | Histidine | 2 | 2014 | 65 | 0.090 |
Why?
| | Jurkat Cells | 3 | 2020 | 138 | 0.090 |
Why?
| | APOBEC-3G Deaminase | 1 | 2010 | 6 | 0.090 |
Why?
| | Signal Transduction | 2 | 2020 | 5068 | 0.080 |
Why?
| | Antigens, Neoplasm | 1 | 2013 | 317 | 0.080 |
Why?
| | Macrophages | 3 | 2009 | 1544 | 0.080 |
Why?
| | vif Gene Products, Human Immunodeficiency Virus | 1 | 2010 | 3 | 0.080 |
Why?
| | Injections | 2 | 2009 | 187 | 0.080 |
Why?
| | Polyradiculoneuropathy | 1 | 2009 | 3 | 0.080 |
Why?
| | Virus Internalization | 1 | 2010 | 66 | 0.080 |
Why?
| | Swine | 2 | 2009 | 796 | 0.080 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2009 | 29 | 0.080 |
Why?
| | Isoenzymes | 1 | 2010 | 303 | 0.080 |
Why?
| | Iris | 1 | 2009 | 21 | 0.080 |
Why?
| | Macaca fascicularis | 1 | 2009 | 68 | 0.080 |
Why?
| | Cyclooxygenase 2 | 1 | 2009 | 176 | 0.080 |
Why?
| | Gene Deletion | 2 | 2002 | 391 | 0.070 |
Why?
| | Intracellular Fluid | 1 | 2008 | 27 | 0.070 |
Why?
| | Protein Processing, Post-Translational | 2 | 2004 | 464 | 0.070 |
Why?
| | Young Adult | 4 | 2020 | 13329 | 0.070 |
Why?
| | Endosomes | 1 | 2010 | 141 | 0.070 |
Why?
| | Recombinant Proteins | 2 | 2009 | 1349 | 0.070 |
Why?
| | Neoplasms | 2 | 2013 | 2712 | 0.070 |
Why?
| | Antigens, Viral | 1 | 2009 | 179 | 0.070 |
Why?
| | Saccharomyces cerevisiae | 1 | 2013 | 552 | 0.070 |
Why?
| | Cell Division | 2 | 2001 | 790 | 0.070 |
Why?
| | Infectious Anemia Virus, Equine | 1 | 2007 | 1 | 0.070 |
Why?
| | rev Gene Products, Human Immunodeficiency Virus | 2 | 2004 | 6 | 0.070 |
Why?
| | RNA Splicing | 2 | 2015 | 270 | 0.070 |
Why?
| | Ubiquitin-Protein Ligases | 2 | 2007 | 175 | 0.070 |
Why?
| | Occupational Diseases | 1 | 2009 | 157 | 0.070 |
Why?
| | United States | 3 | 2020 | 15028 | 0.070 |
Why?
| | Cell Membrane | 3 | 2010 | 713 | 0.070 |
Why?
| | Glaucoma, Open-Angle | 1 | 2009 | 101 | 0.070 |
Why?
| | Antigens, CD34 | 2 | 1998 | 88 | 0.070 |
Why?
| | Leukocytes, Mononuclear | 1 | 2010 | 568 | 0.070 |
Why?
| | Gene Products, pol | 2 | 1998 | 6 | 0.070 |
Why?
| | Models, Genetic | 1 | 2009 | 589 | 0.060 |
Why?
| | Virulence | 1 | 2007 | 267 | 0.060 |
Why?
| | Phylogeny | 1 | 2011 | 1009 | 0.060 |
Why?
| | Defective Viruses | 2 | 2004 | 5 | 0.060 |
Why?
| | Crystallography, X-Ray | 2 | 2020 | 481 | 0.060 |
Why?
| | Binding Sites | 2 | 2021 | 1317 | 0.060 |
Why?
| | Chromosomes, Human | 1 | 2006 | 45 | 0.060 |
Why?
| | Time Factors | 2 | 2009 | 6845 | 0.060 |
Why?
| | Oxidative Stress | 1 | 2012 | 1322 | 0.060 |
Why?
| | Retinal Ganglion Cells | 2 | 2004 | 111 | 0.060 |
Why?
| | Occupational Exposure | 1 | 2009 | 343 | 0.060 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2010 | 748 | 0.060 |
Why?
| | Models, Biological | 1 | 2013 | 1784 | 0.060 |
Why?
| | Avian Leukosis Virus | 1 | 2005 | 6 | 0.060 |
Why?
| | Cell Survival | 1 | 2009 | 1130 | 0.060 |
Why?
| | Peptide Fragments | 1 | 2009 | 691 | 0.060 |
Why?
| | Genes, Regulator | 1 | 2005 | 36 | 0.060 |
Why?
| | Leukemia Virus, Gibbon Ape | 1 | 2005 | 1 | 0.060 |
Why?
| | Protein Structure, Secondary | 1 | 2006 | 373 | 0.060 |
Why?
| | Aged | 6 | 2020 | 23995 | 0.060 |
Why?
| | NIH 3T3 Cells | 1 | 2005 | 146 | 0.060 |
Why?
| | Proteasome Inhibitors | 1 | 2004 | 44 | 0.060 |
Why?
| | Ribonucleases | 1 | 2004 | 47 | 0.060 |
Why?
| | Mitochondria | 1 | 2011 | 951 | 0.060 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2006 | 280 | 0.060 |
Why?
| | Indicators and Reagents | 1 | 2004 | 109 | 0.050 |
Why?
| | Ubiquitin | 1 | 2004 | 72 | 0.050 |
Why?
| | Immunoprecipitation | 1 | 2004 | 152 | 0.050 |
Why?
| | Nuclear Proteins | 1 | 2009 | 709 | 0.050 |
Why?
| | Genes, vpu | 1 | 2004 | 1 | 0.050 |
Why?
| | Hematopoietic Stem Cells | 2 | 1998 | 408 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2374 | 0.050 |
Why?
| | Protease Inhibitors | 1 | 2004 | 109 | 0.050 |
Why?
| | Histones | 1 | 2009 | 636 | 0.050 |
Why?
| | Digestive System Diseases | 1 | 2003 | 26 | 0.050 |
Why?
| | Models, Molecular | 2 | 2022 | 1598 | 0.050 |
Why?
| | Alleles | 2 | 2020 | 888 | 0.050 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2004 | 99 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2007 | 738 | 0.050 |
Why?
| | Adenoviridae | 1 | 2004 | 198 | 0.050 |
Why?
| | Codon, Initiator | 1 | 2002 | 11 | 0.050 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2004 | 276 | 0.050 |
Why?
| | Microscopy, Fluorescence | 1 | 2004 | 413 | 0.050 |
Why?
| | Respirovirus | 1 | 2002 | 6 | 0.050 |
Why?
| | Virus Uncoating | 1 | 2022 | 1 | 0.050 |
Why?
| | Proviruses | 1 | 2002 | 16 | 0.050 |
Why?
| | Eye Diseases | 1 | 2003 | 90 | 0.050 |
Why?
| | Caveolin 1 | 1 | 2002 | 22 | 0.050 |
Why?
| | Laos | 1 | 2002 | 5 | 0.050 |
Why?
| | Immunoenzyme Techniques | 1 | 2002 | 208 | 0.050 |
Why?
| | Apoptosis | 1 | 2011 | 2555 | 0.050 |
Why?
| | Aphidicolin | 1 | 2001 | 5 | 0.050 |
Why?
| | Leukemia Virus, Murine | 1 | 2001 | 19 | 0.050 |
Why?
| | Cell Cycle | 1 | 2005 | 600 | 0.050 |
Why?
| | Lac Operon | 1 | 2001 | 44 | 0.050 |
Why?
| | Respiratory Tract Diseases | 1 | 2003 | 180 | 0.050 |
Why?
| | Capsid Proteins | 1 | 2022 | 94 | 0.050 |
Why?
| | Genetic Markers | 1 | 2002 | 347 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 1 | 2002 | 384 | 0.040 |
Why?
| | Chromosome Mapping | 1 | 2002 | 516 | 0.040 |
Why?
| | Nuclear Pore | 1 | 2021 | 17 | 0.040 |
Why?
| | Catalytic Domain | 1 | 2022 | 228 | 0.040 |
Why?
| | Osteoblasts | 1 | 2002 | 130 | 0.040 |
Why?
| | Organ Specificity | 1 | 2001 | 307 | 0.040 |
Why?
| | Deuterium Exchange Measurement | 1 | 2020 | 29 | 0.040 |
Why?
| | Acute Disease | 1 | 2023 | 1004 | 0.040 |
Why?
| | Nervous System Diseases | 1 | 2003 | 273 | 0.040 |
Why?
| | Amino Acid Motifs | 1 | 2021 | 224 | 0.040 |
Why?
| | Middle Aged | 6 | 2020 | 33509 | 0.040 |
Why?
| | Nuclear Respiratory Factor 1 | 1 | 2020 | 3 | 0.040 |
Why?
| | Phenotype | 2 | 2013 | 3158 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2012 | 2274 | 0.040 |
Why?
| | DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2020 | 17 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2020 | 186 | 0.040 |
Why?
| | HCT116 Cells | 1 | 2020 | 80 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2021 | 568 | 0.040 |
Why?
| | Proteinuria | 1 | 2020 | 98 | 0.040 |
Why?
| | Cryoelectron Microscopy | 1 | 2020 | 190 | 0.040 |
Why?
| | Travel | 1 | 2020 | 136 | 0.040 |
Why?
| | Horses | 1 | 2020 | 197 | 0.040 |
Why?
| | Nucleic Acid Conformation | 1 | 2002 | 722 | 0.040 |
Why?
| | Sheep | 1 | 2022 | 853 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2015 | 1718 | 0.040 |
Why?
| | Neurons | 2 | 1998 | 1593 | 0.040 |
Why?
| | Protein Domains | 1 | 2020 | 289 | 0.040 |
Why?
| | Giant Cells | 1 | 1998 | 22 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2001 | 828 | 0.040 |
Why?
| | Rodentia | 1 | 1998 | 59 | 0.040 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1998 | 34 | 0.040 |
Why?
| | Needs Assessment | 1 | 2020 | 381 | 0.040 |
Why?
| | Drug Therapy, Combination | 2 | 2014 | 1034 | 0.030 |
Why?
| | Cattle | 1 | 2020 | 987 | 0.030 |
Why?
| | Coculture Techniques | 1 | 1998 | 240 | 0.030 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 1998 | 114 | 0.030 |
Why?
| | Aged, 80 and over | 3 | 2008 | 7638 | 0.030 |
Why?
| | Brain | 1 | 2009 | 2725 | 0.030 |
Why?
| | Mutagenesis | 1 | 1998 | 182 | 0.030 |
Why?
| | Health Status Disparities | 1 | 2020 | 298 | 0.030 |
Why?
| | Age Factors | 1 | 2003 | 3285 | 0.030 |
Why?
| | RNA | 1 | 2022 | 926 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1490 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2020 | 718 | 0.030 |
Why?
| | In Situ Hybridization | 1 | 2015 | 318 | 0.030 |
Why?
| | DNA Methylation | 1 | 2020 | 641 | 0.030 |
Why?
| | AIDS Vaccines | 1 | 1995 | 53 | 0.030 |
Why?
| | Receptors, Purinergic | 3 | 1990 | 19 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2014 | 103 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2013 | 3404 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 348 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2014 | 307 | 0.030 |
Why?
| | Vesicular stomatitis Indiana virus | 1 | 2013 | 13 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 758 | 0.030 |
Why?
| | History, 21st Century | 1 | 2014 | 213 | 0.030 |
Why?
| | Topoisomerase II Inhibitors | 1 | 2013 | 26 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 854 | 0.030 |
Why?
| | Virus Diseases | 1 | 2015 | 212 | 0.030 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2013 | 45 | 0.030 |
Why?
| | Tumor Escape | 1 | 2013 | 43 | 0.030 |
Why?
| | Galactose | 1 | 2013 | 33 | 0.020 |
Why?
| | Gene Library | 1 | 2013 | 119 | 0.020 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2013 | 122 | 0.020 |
Why?
| | Succinate Dehydrogenase | 1 | 2013 | 50 | 0.020 |
Why?
| | Fungi | 1 | 2014 | 153 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2012 | 158 | 0.020 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2013 | 124 | 0.020 |
Why?
| | Serine-Arginine Splicing Factors | 1 | 2012 | 23 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 190 | 0.020 |
Why?
| | Biomarkers | 1 | 2023 | 4111 | 0.020 |
Why?
| | Molecular Conformation | 1 | 2012 | 148 | 0.020 |
Why?
| | Receptors, Cell Surface | 2 | 1984 | 392 | 0.020 |
Why?
| | Paraganglioma | 1 | 2013 | 52 | 0.020 |
Why?
| | Immunotherapy | 2 | 2013 | 631 | 0.020 |
Why?
| | DNA Primers | 1 | 2012 | 508 | 0.020 |
Why?
| | Protein Conformation | 1 | 2014 | 944 | 0.020 |
Why?
| | Caspase 9 | 1 | 2011 | 56 | 0.020 |
Why?
| | Doxorubicin | 1 | 2013 | 338 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2003 | 2121 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 1995 | 330 | 0.020 |
Why?
| | Epitopes | 1 | 2013 | 476 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3471 | 0.020 |
Why?
| | Adenosine | 2 | 1990 | 222 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2011 | 435 | 0.020 |
Why?
| | Salt Gland | 1 | 1990 | 1 | 0.020 |
Why?
| | Abattoirs | 1 | 2009 | 2 | 0.020 |
Why?
| | Myelin Basic Protein | 1 | 2009 | 47 | 0.020 |
Why?
| | Indiana | 1 | 2009 | 34 | 0.020 |
Why?
| | Recurrence | 1 | 2013 | 1073 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 1995 | 1032 | 0.020 |
Why?
| | Adipose Tissue | 2 | 1984 | 645 | 0.020 |
Why?
| | Colorado | 1 | 2020 | 4553 | 0.020 |
Why?
| | Air Pollutants, Occupational | 1 | 2009 | 40 | 0.020 |
Why?
| | Cyclic AMP | 1 | 1990 | 219 | 0.020 |
Why?
| | Chlorides | 1 | 1990 | 139 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2013 | 847 | 0.020 |
Why?
| | Minnesota | 1 | 2009 | 166 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2013 | 583 | 0.020 |
Why?
| | Demyelinating Diseases | 1 | 2009 | 85 | 0.020 |
Why?
| | Repressor Proteins | 1 | 2012 | 423 | 0.020 |
Why?
| | Inhalation Exposure | 1 | 2009 | 106 | 0.020 |
Why?
| | Aerosols | 1 | 2009 | 178 | 0.020 |
Why?
| | Binding Sites, Antibody | 1 | 2008 | 41 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2012 | 614 | 0.020 |
Why?
| | Culture Media, Conditioned | 1 | 2008 | 112 | 0.020 |
Why?
| | Hybridomas | 1 | 2008 | 236 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2008 | 187 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2013 | 796 | 0.020 |
Why?
| | Adult | 3 | 2020 | 38063 | 0.020 |
Why?
| | Consensus Sequence | 1 | 2007 | 72 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2009 | 5144 | 0.020 |
Why?
| | Eye | 1 | 2008 | 110 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2011 | 1194 | 0.020 |
Why?
| | Drug Resistance, Multiple, Viral | 1 | 2006 | 10 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2009 | 423 | 0.020 |
Why?
| | Melanoma | 1 | 2013 | 763 | 0.020 |
Why?
| | HIV Protease Inhibitors | 1 | 2006 | 69 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2005 | 116 | 0.010 |
Why?
| | Prostatic Neoplasms | 1 | 2013 | 1055 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2008 | 1260 | 0.010 |
Why?
| | Treatment Failure | 1 | 2006 | 344 | 0.010 |
Why?
| | Clinical Protocols | 2 | 1998 | 267 | 0.010 |
Why?
| | Ethylmaleimide | 1 | 1984 | 18 | 0.010 |
Why?
| | Gene Silencing | 1 | 2005 | 197 | 0.010 |
Why?
| | Guanine Nucleotides | 1 | 1984 | 13 | 0.010 |
Why?
| | Codon | 1 | 2004 | 90 | 0.010 |
Why?
| | PHEX Phosphate Regulating Neutral Endopeptidase | 1 | 2002 | 1 | 0.010 |
Why?
| | Hypophosphatemia, Familial | 1 | 2002 | 4 | 0.010 |
Why?
| | Photoreceptor Cells, Vertebrate | 1 | 2002 | 26 | 0.010 |
Why?
| | Autoantibodies | 1 | 2009 | 1454 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 2022 | 0.010 |
Why?
| | Growth Plate | 1 | 2002 | 37 | 0.010 |
Why?
| | Golgi Apparatus | 1 | 2002 | 100 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 2002 | 409 | 0.010 |
Why?
| | Vitreous Body | 1 | 2002 | 114 | 0.010 |
Why?
| | Blood Platelets | 1 | 1984 | 421 | 0.010 |
Why?
| | Skull | 1 | 2002 | 145 | 0.010 |
Why?
| | In Vitro Techniques | 3 | 1990 | 1088 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 21637 | 0.010 |
Why?
| | Endoplasmic Reticulum | 1 | 2002 | 269 | 0.010 |
Why?
| | Animals, Newborn | 1 | 2002 | 847 | 0.010 |
Why?
| | Lymphocyte Transfusion | 1 | 1998 | 21 | 0.010 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 1998 | 50 | 0.010 |
Why?
| | Adenylyl Cyclases | 2 | 1990 | 63 | 0.010 |
Why?
| | Skin | 1 | 2002 | 753 | 0.010 |
Why?
| | Phenylisopropyladenosine | 2 | 1984 | 4 | 0.010 |
Why?
| | RNA Polymerase III | 1 | 1994 | 28 | 0.010 |
Why?
| | Hydrolysis | 1 | 1995 | 194 | 0.010 |
Why?
| | Gentamicins | 1 | 1994 | 52 | 0.010 |
Why?
| | RNA, Antisense | 1 | 1994 | 17 | 0.010 |
Why?
| | Drug Resistance | 1 | 1994 | 145 | 0.010 |
Why?
| | Selection, Genetic | 1 | 1994 | 271 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2006 | 10832 | 0.010 |
Why?
| | 2-Chloroadenosine | 1 | 1990 | 3 | 0.010 |
Why?
| | Dogfish | 1 | 1990 | 4 | 0.010 |
Why?
| | Colforsin | 1 | 1990 | 48 | 0.010 |
Why?
| | Theophylline | 1 | 1990 | 40 | 0.010 |
Why?
| | Somatostatin | 1 | 1990 | 58 | 0.010 |
Why?
| | Perfusion | 1 | 1990 | 223 | 0.000 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 1994 | 625 | 0.000 |
Why?
| | Adenosine-5'-(N-ethylcarboxamide) | 1 | 1984 | 10 | 0.000 |
Why?
| | Xanthines | 1 | 1984 | 17 | 0.000 |
Why?
| | Radioligand Assay | 1 | 1984 | 37 | 0.000 |
Why?
| | Tritium | 1 | 1984 | 71 | 0.000 |
Why?
| | Guanosine Triphosphate | 1 | 1984 | 90 | 0.000 |
Why?
| | Magnesium | 1 | 1984 | 156 | 0.000 |
Why?
| | Sodium | 1 | 1984 | 200 | 0.000 |
Why?
| | Vasodilator Agents | 1 | 1984 | 326 | 0.000 |
Why?
| | Calcium | 1 | 1984 | 1183 | 0.000 |
Why?
|
|
Poeschla's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|